Loading...
XNYS
RCUS
Market cap1.04bUSD
Jul 28, Last price  
9.85USD
1D
-3.71%
1Q
21.16%
IPO
-44.03%
Name

Arcus Biosciences Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
4.04
EPS
Div Yield, %
Shrs. gr., 5y
15.50%
Rev. gr., 5y
76.65%
Revenues
258m
+120.51%
01,413,0008,353,00015,000,00077,517,000382,882,000112,000,000117,000,000258,000,000
Net income
-283m
L-7.82%
-17,970,000-53,082,000-49,594,000-75,931,000-116,677,00053,000,000-267,000,000-307,000,000-283,000,000
CFO
-170m
L-44.44%
-12,944,000-25,059,000-42,996,000-73,462,000111,170,000-256,171,000438,000,000-306,000,000-170,000,000
Earnings
Aug 04, 2025

Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
IPO date
Mar 15, 2018
Employees
500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
258,000
120.51%
117,000
4.46%
112,000
-70.75%
Cost of revenue
568,000
797,000
406,000
Unusual Expense (Income)
NOPBT
(310,000)
(680,000)
(294,000)
NOPBT Margin
Operating Taxes
1,000
6,000
1,000
Tax Rate
NOPAT
(311,000)
(686,000)
(295,000)
Net income
(283,000)
-7.82%
(307,000)
14.98%
(267,000)
-603.77%
Dividends
Dividend yield
Proceeds from repurchase of equity
228,000
25,000
23,000
BB yield
-16.99%
-1.77%
-1.54%
Debt
Debt current
11,000
3,000
Long-term debt
60,000
11,000
234,000
Deferred revenue
307,000
355,000
Other long-term liabilities
391,000
142,000
140,000
Net debt
(918,000)
(844,000)
(1,030,000)
Cash flow
Cash from operating activities
(170,000)
(306,000)
438,000
CAPEX
(6,000)
(24,000)
(12,000)
Cash from investing activities
(84,000)
194,000
(413,000)
Cash from financing activities
277,000
33,000
33,000
FCF
(307,000)
(702,000)
(192,577)
Balance
Cash
978,000
759,000
1,138,000
Long term investments
107,000
129,000
Excess cash
965,100
860,150
1,261,400
Stockholders' equity
485,000
462,000
657,000
Invested Capital
439,000
460,000
615,000
ROIC
ROCE
EV
Common stock shares outstanding
90,100
74,000
72,000
Price
14.89
-22.04%
19.10
-7.64%
20.68
-48.90%
Market cap
1,341,589
-5.08%
1,413,400
-5.07%
1,488,960
-50.26%
EV
423,589
569,400
458,960
EBITDA
(300,000)
(672,000)
(288,000)
EV/EBITDA
Interest
4,000
2,000
2,000
Interest/NOPBT